A Phase II Study of Paclitaxel Poliglumex (PPX) in Combination With Transdermal Estradiol for the Treatment of Androgen Independent Prostate Cancer After Docetaxel Chemotherapy.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Estradiol; Paclitaxel poliglumex
- Indications Prostate cancer
- Focus Therapeutic Use
- 28 Apr 2017 Biomarkers information updated
- 04 Feb 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 14 Apr 2009 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.